Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share

Novo Nordisk announced a corporate rebrand to "Novo" and disclosed organizational changes on an unspecified date. The company stated the changes represent a new direction as it competes in the obesity treatment market against Eli Lilly. The Danish pharmaceutical manufacturer did not disclose specific details of the organizational restructuring in the available statement.

Next story